June 23, 2022
1 min watch
Save
VIDEO: MAGNITUDE study shows impact on infrequent DNA repair mutations in prostate cancer
In this video, Tanya Dorff, MD, head of the genitourinary cancers program at City of Hope, discusses data from the MAGNITUDE study in prostate cancer presented at ASCO Annual Meeting.
Dorff talks about less frequent mutations in DNA repair highlighted by the study, which provided data on poly(ADP-ribose) polymerase (PARP) inhibition’s positive effects on those mutations.
“When clinicians encounter these less common DNA repair alterations, it is acceptable and perhaps even appropriate to use olaparib in those patients, and as we start to see more data and patients treated, we’ll start to get greater confidence,” Dorff said.
Reference:
- Chi K, et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Dorff reports consulting for Astellas, AstraZeneca, Janssen, Pfizer and SeaGen.
Read more about